Difference between revisions of "Talk:Small cell lung cancer"
Jump to navigation
Jump to search
(Caspian study) |
m |
||
| Line 1: | Line 1: | ||
| + | =CASPIAN study= | ||
Hi, could you please add Caspian study? | Hi, could you please add Caspian study? | ||
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext#seccestitle10 | https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext#seccestitle10 | ||
DO you think durvalumab will become more attractive ICP over atezolizumab due to more liberal scheduling q4 weeks? | DO you think durvalumab will become more attractive ICP over atezolizumab due to more liberal scheduling q4 weeks? | ||
| + | |||
| + | This has been added. Hard to know which will become more attractive - probably a good case for a network meta-analysis to try to estimate which is the more effective and the less toxic! | ||
| + | [[User:Jwarner|Jeremy L. Warner MD, MS]] ([[User talk:Jwarner|talk]]) 20:11, 2 November 2019 (EDT) | ||
Latest revision as of 00:11, 3 November 2019
CASPIAN study
Hi, could you please add Caspian study? https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext#seccestitle10
DO you think durvalumab will become more attractive ICP over atezolizumab due to more liberal scheduling q4 weeks?
This has been added. Hard to know which will become more attractive - probably a good case for a network meta-analysis to try to estimate which is the more effective and the less toxic! Jeremy L. Warner MD, MS (talk) 20:11, 2 November 2019 (EDT)